CG Oncology (CGON) EV/FCF: History & Chart

CG Oncology Inc.(CGON)

Biotechnology · Dallas, TX

$63.67-5.04 (-7.34%)

Delayed quote: Oct 6, 2026, 3:55 PM EDT

About CG Oncology Inc.

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.

Dallas, TX

142 employees

cgoncology.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Arthur Kuan

View full financials

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
CG Oncology Inc. (CGON)	$5.62B	N/A	N/A	N/A	N/A
RadNet, Inc. (RDNT)vs ›	$5.55B	N/A	97.76x	95.40x	108.34x
MiniMed Group, Inc. Common Stock (MMED)vs ›	$5.50B	N/A	N/A	N/A	N/A
Iovance Biotherapeutics, Inc. (IOVA)vs ›	$5.78B	N/A	1.02x	1.02x	1.02x
Kodiak Sciences Inc. (KOD)vs ›	$5.80B	N/A	N/A	N/A	N/A
Kiniksa Pharmaceuticals International, plc (KNSA)vs ›	$5.88B	31.21x	30.49x	54.15x	54.33x
GRAIL Inc. (GRAL)vs ›	$5.88B	N/A	N/A	N/A	N/A
PTC Therapeutics, Inc. (PTCT)vs ›	$5.29B	N/A	10.43x	10.43x	10.43x
Ligand Pharmaceuticals Incorporated (LGND)vs ›	$5.95B	46.23x	89.11x	55.49x	41.54x
CRISPR Therapeutics AG (CRSP)vs ›	$5.21B	N/A	11.36x	56.18x	56.18x

NAME

MARKET CAP

EV/FCF RATIO

TTM

CG Oncology Inc. (CGON)

$5.62B

N/A

RadNet, Inc. (RDNT)vs ›

$5.55B

N/A

97.76x

95.40x